← All trials
NCT06041776
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 28, 2023
- Primary completion
- Apr 30, 2028
- Completion date
- Nov 30, 2029
- First posted
- Sep 18, 2023
- Last posted
- Sep 22, 2023
- Enrollment
- 570
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Betta Pharmaceuticals Co.,Ltd.Lead sponsor
- Jiao Tong UniversityStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.